Meeting
2011 ASCO Annual Meeting
Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with multi-agent chemotherapy.
Authors
S. B. Patel
Department of Medicine, University of Maryland School of Medicine and University of Maryland Greenebaum Cancer Center, Baltimore, MD
S. B. Patel , I. Gojo , M. Tidwell , Y. Ning , X. F. Zhao , E. A. Sausville , M. R. Baer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Citation
J Clin Oncol 29: 2011 (suppl; abstr 6579)
Abstract #
6579
Poster Bd #
35H
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Ponatinib (PON) in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation: Longer-term follow up of the PACE trial.
First Author: Hagop M. Kantarjian
Poster
2023 ASCO Annual Meeting
Report of a chronic myeloid leukemia registry in a low-and middle-income setting.
First Author: Nicolas Anthony Othieno-Abinya
Poster
2019 ASCO Annual Meeting
Allogeneic hematopoietic stem cell transplantation contributes to eradication of minimal residual disease in adult Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with dasatinib.
First Author: Jeremy Chang
Poster
2016 ASCO Annual Meeting
Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
First Author: Koji Sasaki